Rakuten Medical, Inc.
- Biotech or pharma, therapeutic R&D
- Medical device or technology
Rakuten Medical is a clinical and commercial-stage biotech company advancing its investigational Alluminox™ platform, which is based on photoimmunotherapy. The company is developing the platform consisting of drug and device to treat cancers. Its lead asset, ASP-1929, an antibody-dye conjugate targeting EGFR, is currently in a global Phase 3 trial in combination with anti-PD-1 therapy. ASP-1929 has already received marketing approval in Japan since 2021 for unresectable, locally advanced, or recurrent head and neck cancer. As of today, the company has completed over 800 commercial treatments in Japan.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}